DiaMedica Therapeutics (DMAC) Accumulated Expenses (2017 - 2026)

DiaMedica Therapeutics has reported Accumulated Expenses for 10 years, with the latest figure at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 23.35% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (down 23.35% YoY), and the FY2025 full-year result was $3.5 million, down 18.45% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.3 million, down from $3.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $4.3 million in Q4 2024, with the low at $161000.0 in Q1 2023.
• Historically, Accumulated Expenses has averaged $1.8 million across 5 years, with a median of $1.4 million in 2022.
• Annual changes were most pronounced in 2023 — Accumulated Expenses plunged 83.35% — and 2024, when it jumped 1027.33%.
• DiaMedica Therapeutics' Accumulated Expenses stood at $1.4 million in 2022, then plunged by 43.88% to $766000.0 in 2023, then surged by 467.49% to $4.3 million in 2024, then declined by 18.45% to $3.5 million in 2025, then slumped by 33.99% to $2.3 million in 2026.
• The last three Accumulated Expenses figures came in at $2.3 million (Q1 2026), $3.5 million (Q4 2025), and $920000.0 (Q3 2025), per Business Quant data.